In this GEN webinar, our speakers will present new research into iPSC-derived hepatocyte models, how they compare to liver cancer cells lines and why they are a better model for large-scale preclinical drug studies.
During the webinar, you’ll learn about DefiniGEN’s highly characterized iPSC-derived hepatocytes (Opti-HEP) and how they provide a sustainable in vitro platform for ADME and toxicology screening.